Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526103 | 0.82 | MMP12 (0.47) | CYP3A4CYP2C19KDM4EHSD17B10GRM8 | |
| SCHEMBL20364016 | 0.82 | CYP3A4 (0.39) | CYP3A4CYP2C19KDM4ECYP19A1TP53 | |
| SCHEMBL4449939 | 0.82 | MMP12 (0.47) | CYP3A4CYP2C19KDM4EHSD17B10GRM8 | |
| SCHEMBL7416398 | 0.81 | GRM8 (0.38) | CYP3A4CYP2C19KDM4EHSD17B10GRM8 | |
| SCHEMBL5355666 | 0.80 | L3MBTL1 (0.46) | CYP3A4CYP2C19KDM4EHSD17B10GRM8 | |
| SCHEMBL29700737 | 0.79 | KDM4E (0.40) | KDM4E | |
| SCHEMBL5929596 | 0.79 | KCNA5 (0.49) | CYP3A4CYP2C19CYP19A1 | |
| SCHEMBL5160546 | 0.79 | KCNA5 (0.49) | CYP3A4CYP2C19CYP19A1 | |
| SCHEMBL6441268 | 0.79 | LMNA (0.56) | KDM4EL3MBTL1 | |
| SCHEMBL6991 | 0.79 | LMNA (0.56) | KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-20150196889-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS | CANAM BIORESEARCH INC. (CA) | 2015-07-16 | — | — | US | disclosed |
| US-20150196889-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS | CANAM BIORESEARCH INC. (CA) | 2015-07-16 | — | — | US | disclosed |
| US-20150196889-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS | CANAM BIORESEARCH INC. (CA) | 2015-07-16 | — | — | US | disclosed |
| US-8926801-B2 | Methods of electrospray chemical synthesis and device for use therein | CANAM BIORESEARCH INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8926801-B2 | Methods of electrospray chemical synthesis and device for use therein | CANAM BIORESEARCH INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8926801-B2 | Methods of electrospray chemical synthesis and device for use therein | CANAM BIORESEARCH INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20120012453-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS AND DEVICE FOR USE THEREIN | CANAM BIORESEARCH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120012453-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS AND DEVICE FOR USE THEREIN | CANAM BIORESEARCH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120012453-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS AND DEVICE FOR USE THEREIN | CANAM BIORESEARCH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| WO-2010081236-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS AND DEVICE FOR USE THEREIN | CANAM BIORESEARCH INC. (CA) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081236-A1 | METHODS OF ELECTROSPRAY CHEMICAL SYNTHESIS AND DEVICE FOR USE THEREIN | CANAM BIORESEARCH INC. (CA) | 2010-07-22 | — | — | WO | disclosed |
| WO-1993010778-A1 | INHIBITION OF ANGIOGENESIS WITH PYRIDINYLOXAZOLE-2-ONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| EP-0539575-A1 | INHIBITION OF METASTASIS IN PATIENTS HAVING CANCER WITH PYRIDYLOXAZOLE-2-ONES. | MERRELL DOW PHARMA (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992020337-A2 | INHIBITION OF METASTASIS IN PATIENTS HAVING CANCER WITH PYRIDYLOXAZOLE-2-ONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0222358-B1 | CARDIOTONIC HETEROCYCLIC OXAZOLONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0222358-A1 | Cardiotonic heterocyclic oxazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CYP3A4 4754/4885CYP2C19 4800/4885KDM4E 4553/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | CYP3A4 4754/4885CYP2C19 4800/4885KDM4E 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.